Peptide Library

Human study PLS-00181

Association between serum thymosin β4 levels of rheumatoid arthritis patients and disease activity and response to therapy.

Prospective cohort · 40 participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Association between serum thymosin β4 levels of rheumatoid arthritis patients and disease activity and response to therapy.primary · Clinical rheumatology · 2012-06-01 · PMID 22653616 · DOI

Design and participants

Design
Prospective cohort
Population
Patients with rheumatoid arthritis starting DMARD and/or TNF-α blocker therapy, compared with healthy controls.
Conditions
Rheumatoid arthritis
Planned enrollment (registry)
Not reported
Enrolled
40
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Serum Tβ4 was raised in RA patients and positively associated with disease activity. It may help determine or predict resistance to RA treatment. Further study is needed on whether Tβ4 is a suitable therapeutic target for RA inflammation.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Tβ4 was measured only as an endogenous serum biomarker and was never administered, so the study gives no evidence on effects of giving the compound.
    • abstract only: Only the PubMed abstract is available, so methods, funding and conflicts are not reported.
    • small or imprecise: Only 40 RA patients were sampled, which limits the precision of the associations reported.
    • confounding: Treatment groups (DMARD vs DMARD + TNF blocker) were not randomized and differed at baseline, so associations may be confounded.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 22653616, abstract (sentences 8-10) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 22653616, abstract (sentence 2) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 22653616, abstract (sentence 2) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 22653616, abstract (sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).